SWK Holdings Corporation operates as a specialized investment firm in the life sciences sector, committed to providing high-risk-adjusted returns through innovative financing solutions tailored for transformative therapies. The firm's issuance of 9.00% Senior Notes due 2027 exemplifies its active role in funding promising healthcare opportunities. With a robust industry understanding and a strategic investment framework, SWK aims to deliver substantial value to institutional investors while adeptly navigating the complexities of the evolving healthcare market.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | 0.00% |
| Return on Assets | 0.00% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | — |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | 0 |
| Float | 0 |
| % Insiders | 0.00% |
| % Institutions | 0.00% |
Volatility is currently contracting